Article
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Nov 2021
Saalfeld Felix C, Wenzel Carina, Christopoulos Petros, Merkelbach-Bruse Sabine, Reissig Timm M, Laßmann Silke, Thiel Sebastian, Stratmann Jan A, Marienfeld Ralf, Berger Johannes, Desuki Alexander, Velthaus Janna-Lisa, Kauffmann-Guerrero Diego, Stenzinger Albrecht, Michels Sebastian, Herold Thomas, Kramer Michael, Herold Sylvia, Tufman Amanda, Loges Sonja, Alt Jürgen, Joosten Maria, Schmidtke-Schrezenmeier Gerlinde, Sebastian Martin, Stephan-Falkenau Susann, Waller Cornelius F, Wiesweg Marcel, Wolf Jürgen, Thomas Michael, Aust Daniela E, Wermke Martin
Abstract excerpt
INTRODUCTION: In contrast to other driver mutations, no targeted therapies have yet been approved in ERBB2-mutated NSCLC (HER2mu NSCLC). Nevertheless, several compounds have revealed promising early efficacy data, which need to be evaluated in the context of current standard approaches. Although data on the efficacy of immune checkpoint inhibitors (ICIs) in second or subsequent lines of treatment remain limited...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.